Method for synthetizing 1,2,4-trioxane compound and purpose
A synthesis method and compound technology, which are applied in the directions of medical preparations containing active ingredients, organic chemistry, drug combinations, etc., to achieve the effect of convenient synthesis and significant in vitro antimalarial activity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0038]
[0039] 4 (103 mg, 0.60 mmol) was dissolved in anhydrous THF Chinese name (2 mL), NaH (60% in mineral oil Chinese name, 77 mg, 1.92 mmol) was added, stirred at room temperature for 1 h, and HMPA Chinese name (0.24 mL, 1.2 mmol), after 10 min, a THF solution of 5 (300 mg, 1.2 mmol dissolved in 1 mL of anhydrous THF) was added dropwise. Stir overnight at room temperature, dilute with ether and add saturated NH 4 Cl solution quenched the reaction. Extract with ether, combine the organic phases, wash with saturated sodium chloride solution and dry over anhydrous sodium sulfate. Filtration, concentration and flash column chromatography (EtOAc / PE Chinese name = 1:50) gave 6 (160 mg, 0.47 mmol) as a colorless oily liquid with a yield of 78%. 1 H NMR (300MHz, CDCl 3 )δ7.51(t, J=7.0Hz, 2H), 7.30(t, J=7.3Hz, 1H), 7.13(t, J=7.7Hz, 1H), 5.70-5.82(m, 1H), 5.27( d, J=6.4Hz, 1H), 5.23(s, 1H), 4.61(d, J=13.1Hz, 1H), 4.43(d, J=13.3Hz, 1H), 3.90-3.95(m, 4H), 3.80 (dd, J = 5.3, 7...
Embodiment 2
[0041]
[0042] 6 (200 mg, 0.58 mmol) was dissolved in acetonitrile (12 mL) and PPh was added sequentially 3 (60mg, 0.23mmol), K 2 CO 3 (480mg, 3.50mmol) and Pd(OAc) 2 (26 mg, 0.12 mmol). Heated to reflux in an oil bath at 80°C for 36h under an argon atmosphere. Diluted with ether and washed with water to remove inorganic matter, the organic phase was washed with saturated sodium chloride solution and dried over anhydrous sodium sulfate. Filtration, concentration and flash column chromatography (EtOAc / PE=1:20) gave 7 (114mg, 0.44mmol) as a pale yellow liquid. Yield 76%. 1 H NMR (300MHz, CDCl 3 )δ7.62-7.65 (m, 1H), 7.20-7.26 (m, 2H), 7.00-7.03 (m, 1H), 5.64 (s, 1H), 5.08 (s, 1H), 4.87 (d, J= 15.2Hz, 1H), 4.75(d, J=15.3Hz, 1H), 4.33(t, J=6.2Hz, 1H), 3.89-3.98(m, 4H), 1.72-2.06(m, 4H), 1.37( s, 3H). 13 C NMR (75MHz, CDCl 3 )δ141.7, 134.3, 131.4, 127.7, 126.9, 124.3, 123.8, 109.90, 107.0, 77.0, 65.7, 64.6, 64.6, 34.8, 26.9, 23.9; FT-IR (film) 2980, 2880, 1635, 1485, 1...
Embodiment 3
[0044]
[0045] 7 (35 mg, 0.13 mmol) was dissolved in CH 2 Cl 2 (2mL), add Na under ice-water bath 2 CO 3 (8.0 mg, 0.07 mmol) and m-chloroperoxybenzoic acid (m-CPBA, 34 mg, 0.15 mmol, containing 75% m-CPBA). After stirring at room temperature for 5 h, add saturated NaHCO 3 solution and ether. The organic phase was saturated with Na 2 SO 3 The solution was washed with saturated sodium chloride solution and dried over anhydrous sodium sulfate. Filtration, concentration and flash column chromatography (EtOAc / PE=1:10) gave 8 (32 mg, 0.115 mmol) as a colorless viscous liquid with a yield of 89%. 1 H NMR (300MHz, CDCl 3 )δ7.21-7.31(m, 2H), 7.13(t, J=3.8Hz, 1H), 7.03(t, J=3.7Hz, 1H), 4.92(s, 2H), 3.82-4.03(m, 5H ), 3.31(d, J=4.4Hz, 1H), 2.92(d, J=4.7Hz, 1H), 1.94-2.08(m, 1H), 1.55-1.78(m, 2H), 1.39-1.54(m, 1H), 1.34(s, 3H). 13 C NMR (75MHz, CDCl 3 )δ137.5, 133.6, 127.7, 127.1, 123.5, 123.2, 109.8, 68.1, 64.7, 64.6, 55.9, 54.0, 35.1, 23.9, 23.7; FT-IR (film) 2979, 2878,...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 